Carrera Capital Advisors Reduces Holdings in Thermo Fisher Scientific Inc. $TMO

Carrera Capital Advisors decreased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 11.1% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 726 shares of the medical research company’s stock after selling 91 shares during the quarter. Carrera Capital Advisors’ holdings in Thermo Fisher Scientific were worth $295,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. CBIZ Investment Advisory Services LLC lifted its holdings in Thermo Fisher Scientific by 137.5% during the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 33 shares in the last quarter. Anderson Financial Strategies LLC purchased a new position in Thermo Fisher Scientific during the first quarter valued at approximately $30,000. Keystone Global Partners LLC purchased a new position in Thermo Fisher Scientific during the first quarter valued at approximately $31,000. IMA Advisory Services Inc. purchased a new position in Thermo Fisher Scientific during the first quarter valued at approximately $35,000. Finally, Smallwood Wealth Investment Management LLC purchased a new position in Thermo Fisher Scientific during the first quarter valued at approximately $37,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Raymond James Financial reissued an “outperform” rating and issued a $535.00 target price (up previously from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Citigroup boosted their price objective on shares of Thermo Fisher Scientific from $500.00 to $580.00 and gave the company a “neutral” rating in a research report on Thursday. JPMorgan Chase & Co. upped their price target on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a report on Thursday, October 9th. Weiss Ratings restated a “hold (c)” rating on shares of Thermo Fisher Scientific in a report on Tuesday, October 14th. Finally, Royal Bank Of Canada set a $561.00 price target on shares of Thermo Fisher Scientific and gave the stock an “outperform” rating in a report on Tuesday, September 2nd. Nineteen equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $595.75.

Insider Activity

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 400 shares of the stock in a transaction dated Friday, September 5th. The shares were sold at an average price of $500.50, for a total transaction of $200,200.00. Following the completion of the sale, the chief executive officer directly owned 113,762 shares of the company’s stock, valued at approximately $56,937,881. This represents a 0.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the sale, the chief accounting officer directly owned 2,319 shares of the company’s stock, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 29,666 shares of company stock valued at $13,990,971. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Up 0.2%

NYSE:TMO opened at $573.07 on Friday. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $610.97. The company has a 50-day moving average of $504.04 and a 200 day moving average of $453.30. The firm has a market cap of $216.40 billion, a PE ratio of 33.11, a price-to-earnings-growth ratio of 3.24 and a beta of 0.77. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.50.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The company had revenue of $11.12 billion during the quarter, compared to analyst estimates of $10.90 billion. During the same period in the prior year, the firm earned $5.28 earnings per share. The firm’s revenue for the quarter was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.